KRAS and cancer: However, in the presence of oncogenic mutations like KRAS, TP53, SMAD4, and CDKN2A, genetically altered epithelial cells transform into cancer cells and disrupt normal communications between PSCs and immune and vascular cells, creating a favorable microenvironment for cancer progression (Figure 2(c)) [21].